ArticleClinical and translational allergy2025
Exploring the impact of chronic urticaria profile as a key predictor of alexithymia: A cross-sectional study.
Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Factors Influencing Acceptance of Biologics and Small Molecule Targeted Drugs Among Patients with Chronic Spontaneous Urticaria: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Biopsychosocial Insights on Adolescents With Chronic Urticaria: The Role of Eosinophils and Stress Coping Strategies.Clinical and translational allergy · 2025Article
- Exploring the impact of chronic urticaria profile as a key predictor of alexithymia: A cross-sectional study.Clinical and translational allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
introductionThe relationship between chronic urticaria (CU) and alexithymia, a cognitive-affective impairment characterized by difficulty in identifying and expressing emotions, is complex and underexplored. This study aimed to identify predictors of alexithymia in CU patients by focusing on the impact of coexisting mental illnesses and antihistamine use.
methodsAn online survey was distributed to specialized allergy and dermatology centers from 2021 to 2022. The survey included the TAS-20, UAS-7, UCT, CU-Q2oL, and demographic information. Participants were 18-80 years old, diagnosed with CU, and had no prior diagnosis of alexithymia. The final analysis included a total of 332 respondents from various countries. Regression models were used to investigate the relationship between clinical and demographic factors of patients with CU as key predictors of alexithymia.
resultsAmong CU patients, the main predictors of having alexithymia were: presenting mental (OR = 2.406, p < 0.05) and cardiovascular comorbidities (OR = 2.085, p < 0.05), active urticaria (as opposed to being urticaria-free), OR = 1.989, p < 0.05, severe impact on quality of life (OR = 1.973, p < 0.01), and the use of oral first-generation antihistamines (OR = 2.340, p < 0.05). The duration of chronic urticaria diagnosis and other types of treatments (sg-AH use, omalizumab use, and corticosteroid use) do not appear to be significantly associated with alexithymia.
conclusionsAlexithymia is closely linked to clinical and demographic variables among patients with CU. These findings suggest that comprehensive management of CU should include psychological assessment and support, especially for patients with alexithymia and those using fg-AH. Reducing the reliance on fg-AH and addressing mental health issues may improve outcomes for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.